ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

FDA News: Zydelig approved in three B-cell blood cancers

August 1, 2014

News Analysis: The Political Economy of Importation to Alleviate Cancer Drug Shortages

March 2, 2012

Funding opportunities listed.

April 23, 2004

Six NY Institutes Form Cancer Vaccine Collaboration

November 8, 2002

Panitumumab Improves PFS In Metastatic Colon Cancer

April 28, 2006

Also AACI honors MIT’s Robert Weinberg. Bernard Fisher wins two awards.

November 21, 2003